Strategy+ is advising one of the world’s premier biopharmaceutical companies Pfizer (NYSE: PFE) on the merger of its off-patent branded and generic established medicines business, Upjohn with Mylan (Nasdaq: MYL). The deal resulted in the creation of a new global pharmaceutical company, Viatris (NASDAQ: VTRS). The definitive agreement was announced July 29, 2019. The all-stock, Reverse Morris Trust transaction was valued at $12 Billion.
Note to Editors: This press release may contain forward-looking statements regarding Strategy+’s intentions and interests. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied in these statements. The firm does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
